phase

Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment Technology

Source Node:
Time Stamp: April 15, 2024 1:26 PM - Modified On: April 15, 2024 - Published By:
Source Cluster:
Republished By Plato

  Company is targeting pancreatic cancer pain with advanced nerve detection and treatment technology New York, March 12, 2024 - (Plato Data) - Benzinga has published a new article on Autonomix Medical Inc. (NASDAQ: AMIX), featuring the company's groundbreaking approach to peripheral nervous system (PNS) disorders. The Benzinga article delves into the critical role of the PNS in human health and highlights how Autonomix Medical is pioneering with its catheter-based microchip sensing array technology. The article provides a comprehensive look at how Autonomix Medical is redefining treatment protocols for nerve-related

Moxy.io Welcomes Former UBS CFO Thomas Gustinis to Its Executive Team and to the board of the Moxy Foundation

Source Node:
Time Stamp: April 10, 2024 2:27 PM - Modified On: April 10, 2024 - Published By:
Source Cluster:
Republished By Plato

Zug, Switzerland – Moxy.io proudly announces the appointment of Thomas Gustinis, a key figure in treasury management of UBS, as its previous Global Chief Financial Officer. This landmark hire underscores Moxy.io’s ambition to fortify its leadership team with unparalleled financial expertise and vision, propelling the company towards new horizons in the competitive blockchain and gaming industries. Thomas Gustinis brings to Moxy.io a storied career in global finance, having helmed UBS's treasury operations, where he was instrumental in steering the banking giant through complex financial landscapes and maximizing operational efficiency and

Passage of the Amendment to the Advanced Regenerative Biotech Act a Positive Catalyst for Korean and Japanese Cell Therapy Companies

Source Node:
Time Stamp: February 7, 2024 10:50 AM - Modified On: February 7, 2024 - Published By:
Source Cluster:
Republished By Plato

Legislation Puts Renewed Focus on Next-Generation NK Cell Therapies New York, Feb 7, 2024 - (Plato Data) - On Thursday February 2, 2024, the bio industry welcomed the parliament’s passage of a bill that adds regenerative medicine organizations to the list of those considered for human cell management business licenses. The National Assembly passed the “Amendment to the Act on Safety and Support for Advanced Regenerative Medicine and Advanced Biopharmaceuticals” in a plenary session paving the way for certain next generation NK Cell Therapy companies to recognized as a licensed

Lindsay Rosenwald’s Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from Subsidiaries

Source Node:
Time Stamp: February 2, 2024 2:30 PM - Modified On: February 2, 2024 - Published By:
Source Cluster:
Republished By Plato

  New York, Feb 2, 2024 - (Plato Data)- Fortress Biotech (Fortress Bio), a unique biotech company led by industry veteran Dr. Lindsay Rosenwald, focused on identifying, in-licensing and developing high-potential marketed drugs and development-stage drug candidates in-house and through its subsidiary partner companies, has announced multiple new milestones to start 2024 with a bang. Avenue Therapeutics Finalizes Phase 3 Study for IV Tramadol with FDA Avenue Therapeutics, a subsidiary of Fortress Bio, has reached a significant milestone in its quest to introduce new therapies for neurologic diseases. The company

Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate

Source Node:
Time Stamp: January 29, 2024 6:55 AM - Modified On: January 29, 2024 - Published By:
Source Cluster:
Republished By Plato

New York, Jan. 29, 2024 - (Plato Data) - Corbus Pharmaceuticals (NASDAQ:CRBP) jumped on Friday after announcing positive data from a small group of cancer patients who received its antibody-drug conjugate (ADC) CRB-701 in a Phase 1 trial. Citing a December data cut in patients with cancers expressing a tumor-associated antigen called nectin-4, Corbus (CRBP) said that CRB-701 led to an objective response rate (ORR) of 43%, including three partial responses. The data from the first eighteen participants who received the first six dose levels represented the readout, which was

Tokens Fueling Innovation in the Dynamic Fantom DeFi Ecosystem

Source Node:
Time Stamp: January 11, 2024 11:56 AM - Modified On: January 11, 2024 - Published By:
Source Cluster:
Republished By Plato

In the rapidly evolving realm of Defi and L1’s, the Fantom ecosystem shines as a vibrant hub for innovation. Within this dynamic landscape, various protocols play pivotal roles in sculpting the future of decentralized finance on Fantom. Each protocol brings its distinct features, vision, and potential to the forefront, propelling growth, stability, and inclusivity within the Fantom DeFi ecosystem. The most known protocol in Fantom is SpookySwap (Ticker : BOO), an EVM-compatible DEX, has been pioneered since its April 2021 launch. Endorsed by the Fantom Foundation and bolstered by community

NKGen Biotech Advances Alzheimer’s Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial

Source Node:
Time Stamp: December 29, 2023 3:07 AM - Modified On: December 29, 2023 - Published By:
Source Cluster:
Republished By Plato

December 29, 2023 - NKGen Biotech, Inc. (Nasdaq: NKGN) is making strides in Alzheimer's disease (AD) treatment with the dosing of the first patient in its Phase 1/2a trial for SNK01, an autologous natural killer (NK) cell therapy. The innovative product, designed for moderate AD, has demonstrated promising results in neuroinflammation and cognitive function during its Phase 1 safety trial. Key Points: SNK01 Efficacy: NKGen's SNK01, a cryopreserved autologous NK cell therapy, showed improvement in neuroinflammation and cognitive function in the Phase 1 dose-escalation safety trial. The therapy boasts enhanced

Paribus Embracing DAO transition.

Source Node:
Time Stamp: December 22, 2023 3:10 PM - Modified On: December 22, 2023 - Published By:
Source Cluster:
Republished By Plato

In our journey of developing Paribus, we’ve received a lot of feedback from our community, primarily positive and helpful. But, as is often the case when a small team controls a platform, not everyone agrees with our decisions. At every step, we’ve tried to make the best choices based on the information we had. We’ve always known that, eventually, it would be the community’s turn to take the lead in guiding Paribus. And, as we announced in our recent X-space update, that time is approaching fast with the release of

JCB, IDEMIA and Soft Space launch “JCBDC” Phase 2 pilot to trial CBDC offline P2P payments

Source Node:
Time Stamp: December 13, 2023 6:49 AM - Modified On: December 13, 2023 - Published By:
Source Cluster:
Republished By Plato

Tokyo, Paris, Kuala Lumpur, Dec 13, 2023 - (JCN Newswire) - Japan's only international payment brand JCB Co., Ltd. ("JCB") has launched the “JCBDC” (JCB Digital Currency) Phase 2 pilot project with IDEMIA, a global leader in identity technologies, and the world’s leading fintech company Soft Space Sdn Bhd. ("Soft Space"). In Phase 1 of the JCBDC project, JCB, IDEMIA, and Soft Space developed a CBDC (Central Bank Digital Currency) payment solution, enabling merchants to accept CBDC without the need to modify their POS (point of sale) terminals and payment

IQPay announces Lead Investor Steven Freidmutter Joins IQPay’s Advisory Board

Source Node:
Time Stamp: October 31, 2023 6:13 AM - Modified On: October 31, 2023 - Published By:
Source Cluster:
Republished By Plato

  Johannesburg 25 October 2023 -, IQPay an innovative force in the fintech landscape, is elated to announce that Steven Freidmutter has officially joined its advisory board. Adding to this significant appointment, Freidmutter is also stepping in as the lead investor for IQPay, marking a milestone in the company's journey. Steven Freidmutter brings to IQPay an impressive track record of experience, presence and credibility. Freidmutter's journey continues to defy conventions. His recent appointment as a partner and founding advisory board member of the Boston-based VC fund Erez Capital is a

NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.

Source Node:
Time Stamp: October 24, 2023 11:55 AM - Modified On: October 24, 2023 - Published By:
Source Cluster:
Republished By Plato

Summary: Progress in Neurodegenerative Research:  NKGen’s Phase 1/2a Clinical Trial for SNK01 on Track for End-of-Year Initiation SANTA ANA, Calif., Oct. 24, 2023 (Plato / Amplifi) -- Today, NKGen Biotech Inc. (Nasdaq: NKGN), a trailblazer in the field of autologous, allogeneic, and CAR-NK natural killer cell therapeutics, proudly announced the progression of its SNK01 program targeting Alzheimer’s Disease (AD), backed by the green light from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. NKGen is gearing up to initiate its Phase 1/2a clinical trial

Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases

Source Node:
Time Stamp: October 13, 2023 5:17 AM - Modified On: October 13, 2023 - Published By:
Source Cluster:
Republished By Plato

  In the United States, heart disease accounts for a significant number of deaths every year, with cardiovascular disease being the primary concern. Factors like lifestyle choices and unforeseen circumstances contribute to its prevalence. Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the heart's lining) are two inflammatory heart conditions primarily linked to immunological reactions from viral infections and mRNA vaccines. Though considered rare, awareness of these conditions is growing, especially among younger populations. Recent research in Science Immunology highlighted an increase in cytokine production leading to myocarditis